Therapeutic human anti-il-1r1 monoclonal antibody
CA 2824167 C · Owner: Medarex, L.L.C. · Inventors: Huang, Haichun; Qian, Xueming; Martin, Francis Hall
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 5, 2003 and granted September 25, 2018. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 5, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 5, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.